Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Talking Healthtech

- PMLiVE

GSK withdraws melanoma combo in EU

EMA says it needs more data to review Mekinist and Tafinlar

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

Novartis building

Novartis skin cancer drug clears pivotal trial

Sonidegib achieves significant response in basal cell carcinoma patients

- PMLiVE

Merck shares jump on melanoma drug filing

MK-3475 could be approved by end of 2014

- PMLiVE

FDA approves GSK’s combo cancer treatment

US regulator backs Mekinist and Tafinlar to treat melanoma

- PMLiVE

Almirall expands in US via $400m deal to buy Aqua

Will boost its standing in dermatology

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

Merck’s melanoma drug shows survival benefit

MK-3475 shows promise in phase Ib

Merrill Brink pharmacovigilance

Pharmacovigilance and adverse event reporting: Five keys for establishing worldwide best practice

Pharmacovigilance, an arm of patient care with a charter to make the best use of medicines and data for the treatment or prevention of disease, is taking on growing importance...

Merrill Brink International

- PMLiVE

Setback for GSK as melanoma vaccine misses targets

Cancer immunotherapy disappoints in phase III

- PMLiVE

GSK melanoma therapy Tafinlar cleared in EU

Follows approvals for skin cancer drug in US, Canada and Australia

O2 Health hangs up on UK telehealth plans

Recognises eHealth potential but says uptake was slower than expected

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links